| Title : Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis - Javle_2009_Cancer.Invest_27_193 |
| Author(s) : Javle MM , Yang G , Nwogu CE , Wilding GE , O'Malley L , Vinjamaram S , Schiff MD , Nava HR , LeVea C , Clark KR , Prey JD , Smith PF , Pendyala L |
| Ref : Cancer Invest , 27 :193 , 2009 |
|
Abstract :
PURPOSE: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer. PATIENTS AND METHODS: Oxaliplatin (85 mg/m(2)) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m(2) with 50.4 Gy radiation. RESULTS: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p |
| PubMedSearch : Javle_2009_Cancer.Invest_27_193 |
| PubMedID: 19235592 |
| Substrate | Capecitabine |
Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L (2009)
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis
Cancer Invest
27 :193
Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L (2009)
Cancer Invest
27 :193